推薦產品
化驗
≥98% (HPLC)
形狀
powder
藥物控制
USDEA Schedule II; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)
儲存條件
desiccated
顏色
white to beige
溶解度
H2O: 1 mg/mL, clear
儲存溫度
2-8°C
InChI
1S/C22H30N2O2S.C6H8O7/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-10,17H,3,11-16,18H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
InChI 密鑰
OJCZPLDERGDQRJ-UHFFFAOYSA-N
尋找類似的產品？ 前往 產品比較指南
生化／生理作用
Sufentanil is a mu-opioid selective agonist, 10 times more potent than fentanyl, over 1000 times more potent than morphine. Sufentanil citrate is used as an analgesic and anesthesia adjunct. There are some differences in activity and selectivity among the mu-opiate agonist analgesics. Receptor-internalizing agonists like beta-endorphin, methadone, fentanyl, and sufentanil have been found to induce NADH/NADPH-mediated reactive oxygen species (ROS) synthesis via Phospholipase D-dependent signaling pathways whereas agonists like morphine that do not induce receptor endocytosis failed to activate ROS synthesis. In another report meperidine, remifentanil and tramadol were found to interact with alpha(2)-adrenoceptors, whereas sufentanil did not.
訊號詞
Danger
危險分類
Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral
儲存類別代碼
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Criteria for use of fentanyl citrate, sufentanil citrate, and alfentanil hydrochloride.
G B Satterlee et al.
Clinical pharmacy, 10(8), 635-637 (1991-08-01)
C E Rosow
Pharmacotherapy, 4(1), 11-19 (1984-01-01)
Sufentanil citrate is a potent analogue of fentanyl that has been evaluated primarily for use in opioid anesthesia. It is a pure mu receptor agonist and produces the typical spectrum of opioid effects. The major side effects are truncal rigidity
T I Saari et al.
British journal of anaesthesia, 113(4), 677-687 (2014-07-09)
Our objective was to evaluate the effect of intensive care treatment on the protein binding of sufentanil and hydromorphone in cardiac surgery patients during postoperative analgesia using a target-controlled infusion (TCI) and patient-controlled analgesia (PCA). Fifty adult patients were enrolled
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務